Compare Jumia Technologies AG - ADR (JMIA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs BIO-TECHNE Corp — how do they compare? Jumia Technologies AG - ADR trades at $5.95 (market cap $743.12M), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is far larger — about 15.1× Jumia Technologies AG - ADR's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| JMIA | TECH | |
|---|---|---|
Market Cap | $743.12M | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $72.29 |
52-Week Low | $5.69 | $43.31 |
Enterprise Value | $690.21M | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.19, up 8.79% today, but remains in a bearish technical trend with mixed signals from moving averages and oscillators. Fundamentally, the company shows improving revenue trends ($189M in 2025) and narrowing losses, though it continues to post negative net income margins (-30.79%). Recent news highlights management's focus on achieving profitability by 2027 through strategic partnerships and expansion initiatives.
While analyst consensus remains strongly bullish (71% buy ratings), JMIA faces significant execution risks in its path to profitability. The stock presents speculative upside potential if the company can deliver on its 2027 profitability targets, but investors should weigh the substantial losses against the promising revenue growth trajectory in African e-commerce markets.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
